Research programme: autoimmune disease therapy - Domantis/Tanox

Drug Profile

Research programme: autoimmune disease therapy - Domantis/Tanox

Alternative Names: Autoimmune disease therapy research programme - Domantis/Tanox; Dom0800; Domain antibody therapy research programme - Domantis/Tanox

Latest Information Update: 04 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Domantis; Tanox
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders

Most Recent Events

  • 04 May 2007 No development reported - Preclinical for Autoimmune disorders in United Kingdom (unspecified route)
  • 07 Jan 2007 Domantis has been acquired by GlaxoSmithKline
  • 04 Apr 2005 Preclinical trials in Autoimmune disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top